Skip Navigation
Search Menu
Johns Hopkins Medicine International

In This Section      
Print This Page

Cancer

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Patients at the Hopkins Kimmel Cancer Center have access to some of the most innovative and advanced therapies in the world.

Because Kimmel Cancer Center research scientists and clinicians work closely together, new drugs and treatments developed in the laboratory are quickly transferred to the clinical setting, offering patients constantly improved therapeutic options.

The Kimmel Cancer Center is one of only 45 cancer centers in the United States designated by the National Cancer Institute as a Comprehensive Cancer Center, providing a wide spectrum of specialty programs for adults and children:

  • Blood and bone marrow cancers
  • Brain and spinal tumor program
  • Breast center
  • Colon cancer center
  • Gynecologic oncology program
  • Head and neck cancer center
  • Liver cancer center
  • Lung cancer program
  • Melanoma program
  • Pancreatic cancer center
  • Pediatric oncology
  • Prostate cancer and other genitourinary cancers

The Kimmel Cancer Center also offers complete family and patient services that include a Cancer Counseling Center, survivors and palliative care programs, and the Hackerman-Patz Patient and Family Pavilion for patients and their families traveling from out-of-town.

To learn more or to make an appointment, call +1-410-502-7683.

Discover Our Research

Vaccine Clears Some Precancerous Cervical Lesions in Clinical Trial
Scientists have used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial. The goal, say the scientists, was to find nonsurgical ways to treat precancerous lesions caused by HPV. Read more about the findings.


Men with Low-Risk Prostate Cancer in Active Surveillance Program Not Likely to Succumb to the Disease, Study Shows
Men with relatively unaggressive prostate tumors and whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to results of a study by researchers at the Brady Urological Institute at Johns Hopkins, who analyzed survival statistics up to 15 years.  Learn more about this research.


Virtual testing of new cancer drug therapies to speed clinical trials
While new drugs offer the promise of treating cancer, their approval rate through clinical trials is dismally low: Only about 7 percent get a thumbs up. But the emerging medical field of computational medicine gives researchers far better odds of creating medications that pass more quickly through trials and provide effective treatment for a wide range of cancer patients. Read more about this breakthrough.